UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

     

SCHEDULE 13G

 

Under the Securities Exchange Act of 1934

 

Galera Therapeutics, Inc.

 

(Name of Issuer)

Common Shares

 

(Title of Class of Securities)

36338D108

 

(CUSIP Number)

February 4, 2022

 

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

o Rule 13d-1(b)
x Rule 13d-1(c)
o Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 
 

CUSIP No. 36338D108 13G Page 2 of 9 Pages

 

  1. NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

Rosalind Advisors, Inc.
 
  2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)
    (a) o
    (b) o
 
  3. SEC USE ONLY
 
  4. CITIZENSHIP OR PLACE OF ORGANIZATION
ONTARIO, CANADA
     

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

5. SOLE VOTING POWER
0
 
6. SHARED VOTING POWER
1,543,783
 
7. SOLE DISPOSITIVE POWER
0
 
8. SHARED DISPOSITIVE POWER
1,543,783
 
  9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,543,783
 
  10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)   o
 
  11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
5.8%1
 
  12. TYPE OF REPORTING PERSON (see instructions)
CO

 

 

1   This percentage is calculated based upon 26,438,767 shares of the Issuer's common stock outstanding as of November 5th, 2021 in accordance with 10-Q filed on November 10th, 2021.

 
 

CUSIP No. 36338D108 13G Page 3 of 9 Pages

 

  1. NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

Steven Salamon
 
  2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (aee instructions)
    (a) o
    (b) o
 
  3. SEC USE ONLY
 
  4. CITIZENSHIP OR PLACE OF ORGANIZATION
ONTARIO, CANADA
     

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

5. SOLE VOTING POWER
0
 
6. SHARED VOTING POWER
1,543,783
 
7. SOLE DISPOSITIVE POWER
0
 
8. SHARED DISPOSITIVE POWER
1,543,783
 
  9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,543,783
 
  10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)   o
 
  11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
5.8%1
 
  12. TYPE OF REPORTING PERSON (see instructions)
IN

 

 

1   This percentage is calculated based upon 26,438,767 shares of the Issuer's common stock outstanding as of November 5th, 2021 in accordance with 10-Q filed on November 10th, 2021.

 
 

CUSIP No. 36338D108 13G Page 4 of 9 Pages

 

  1. NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

Gilad Aharon
 
  2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)
    (a) o
    (b) o
 
  3. SEC USE ONLY
 
  4. CITIZENSHIP OR PLACE OF ORGANIZATION
ONTARIO, CANADA
     

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

5. SOLE VOTING POWER
0
 
6. SHARED VOTING POWER
1,543,783
 
7. SOLE DISPOSITIVE POWER
0
 
8. SHARED DISPOSITIVE POWER
1,543,783
 
  9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,543,783
 
  10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)   o
 
  11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
5.8%1
 
  12. TYPE OF REPORTING PERSON (see instructions)
IN

 

 

1   This percentage is calculated based upon 26,438,767 shares of the Issuer's common stock outstanding as of November 5th, 2021 in accordance with 10-Q filed on November 10th, 2021.

 
 

CUSIP No. 36338D108 13G Page 5 of 9 Pages

 

  1. NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

Rosalind Master Fund L.P.
 
  2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)
    (a) o
    (b) o
 
  3. SEC USE ONLY
 
  4. CITIZENSHIP OR PLACE OF ORGANIZATION
CAYMAN ISLANDS
     

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

5. SOLE VOTING POWER
0
 
6. SHARED VOTING POWER
1,543,783
 
7. SOLE DISPOSITIVE POWER
0
 
8. SHARED DISPOSITIVE POWER
1,543,783
 
  9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,543,783
 
  10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)   o
 
  11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
5.8%1
 
  12. TYPE OF REPORTING PERSON (see instructions)
PN

 

 

1   This percentage is calculated based upon 26,438,767 shares of the Issuer's common stock outstanding as of November 5th, 2021 in accordance with 10-Q filed on November 10th, 2021.

 
 

CUSIP No. 36338D108 13G Page 6 of 9 Pages

 

Item 1.
 
  (a) Name of Issuer: Galera Therapeutics, Inc.
  (b) Address of Issuer’s Principal Executive Offices
2 W. Liberty Blvd #100
Malvern, Pennsylvania
       
Item 2.
 
  (a)

Name of Person Filing

Rosalind Advisors, Inc. (“Advisor” to RMF)

Rosalind Master Fund L.P. (“RMF”)

Steven Salamon (“President”)

Steven Salamon is the portfolio manager of the Advisor which advises RMF.

Gilad Aharon is the portfolio manager and member of the Advisor which advises RMF.

  (b)

Address of the Principal Office or, if none, residence
Rosalind Advisors, Inc.

175 Bloor Street East

Suite 1316, North Tower

Toronto, Ontario

M4W 3R8 Canada

 

Rosalind Master Fund L.P.

P.O. Box 309

Ugland House, Grand Cayman

KY1-1104, Cayman Islands

 

Steven Salamon

175 Bloor Street East

Suite 1316, North Tower

Toronto, Ontario

M4W 3R8 Canada

 

Gilad Aharon

175 Bloor Street East

Suite 1316, North Tower

Toronto, Ontario

M4W 3R8 Canada

  (c)

Citizenship

Rosalind Advisors, Inc.: Ontario, Canada
Rosalind Master Fund L.P.: Cayman Islands
Steven Salamon: Ontario, Canada
Gilad Aharon: Ontario, Canada

  (d) Title of Class of Securities
Common Stock
  (e) CUSIP Number
36338D108
 
 

CUSIP No. 36338D108 13G Page 7 of 9 Pages

 

Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
   
  (a) o Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
       
  (b) o Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
       
  (c) o Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
       
  (d) o Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
       
  (e) o An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).
       
  (f) o An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).
       
  (g) o A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G).
       
  (h) o A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
       
  (i) o A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
       
  (j) o Group, in accordance with § 240.13d–1(b)(1)(ii)(J).
Item 4. Ownership.
       
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
 
  (a)

Amount beneficially owned:

Rosalind Master Fund L.P. is the record owner of 1,543,783 shares of common stock.

Rosalind Advisors, Inc. is the investment advisor to RMF and may be deemed to be the beneficial owner of shares held by RMF. Steven Salamon is the portfolio manager of the Advisor and may be deemed to be the beneficial owner of shares held by RMF. Notwithstanding the foregoing, the Advisor and Mr. Salamon disclaim beneficial ownership of the shares.

  (b)

Percent of class:

Rosalind Advisors, Inc. - 5.8%
Rosalind Master Fund L.P. - 5.8%
Steven Salamon - 5.8%

 
 

CUSIP No. 36338D108 13G Page 8 of 9 Pages

 

  (c)

Number of shares as to which the person has:

 

    (i)

Shared power to vote or to direct the vote

Rosalind Advisors, Inc. - 1,543,783
Rosalind Master Fund L.P. - 1,543,783
Steven Salamon - 1,543,783
Gilad Aharon - 1,543,783

    (ii)

Sole power to dispose or to direct the disposition of - 0

    (iii)

Shared power to dispose or to direct the disposition of

Rosalind Advisors, Inc. - 1,543,783
Rosalind Master Fund L.P. - 1,543,783
Steven Salamon - 1,543,783
Gilad Aharon - 1,543,783

 
Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).
 
Item 5. Ownership of Five Percent or Less of a Class.
   
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following   o.
 

Instruction. Dissolution of a group requires a response to this item.

 
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
   
Item 7-9. Not Applicable

 
 

CUSIP No. 36338D108 13G Page 9 of 9 Pages

 

Item 10. Certification.
   

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

    2/11/2022
   

Date

     
   

/s/ Steven Salamon

    Signature
       
   

Steven Salamon/President Rosalind Advisors, Inc.

    Name/Title
 
 

EXHIBIT A

 

JOINT FILING AGREEMENT

 

The undersigned hereby agree that this Statement on Schedule 13G with respect to the beneficial ownership of shares of Common Stock of Galera Therapeutics, Inc. is filed jointly, on behalf of each of them.

 

  Rosalind Advisors, Inc.
  By: /s/ Steven Salamon 
  Name: Steven Salamon
  Title: President
     
  Rosalind Master Fund L.P.
  By: /s/ Mike McDonald 
 

Name: Mike McDonald

 

Title: Director, Rosalind (Cayman) Ltd.
(as General Partner to Rosalind Master Fund)

     
  By: /s/ Steven Salamon  
 

Name: Steven Salamon